Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

All the vital news, analysis, and commentary curated by our industry experts.

$3500

Buy Report

Published: March 31, 2022 Report Code: GMDGDHC22025TDB-ST

Report Overview
Key Players
Table of Contents
Table
Figures
FAQs

Tyrosine Protein Kinase JAK1 pipeline market research report provides comprehensive information on the Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects.

Key MoA in the Tyrosine Protein Kinase JAK1 Pipeline Market

The key MoA in the Tyrosine Protein Kinase JAK1 pipeline market is Tyrosine Protein Kinase JAK1 Inhibitor.

Key RoA in the Tyrosine Protein Kinase JAK1 Pipeline Market

The key RoA in the Tyrosine Protein Kinase JAK1 pipeline market are oral, topical, ophthalmic, cutaneous, inhalational, and intravitreal. Oral has the highest pipeline products.

Tyrosine Protein Kinase JAK1 Pipeline Market, by RoA

For more RoA insights, download a free report sample

Key Molecule Types in the Tyrosine Protein Kinase JAK1 Pipeline Market

The key molecule types in the Tyrosine Protein Kinase JAK1 pipeline market is small molecule.

Key Companies in the Tyrosine Protein Kinase JAK1 Pipeline Market

The key companies in the Tyrosine Protein Kinase JAK1 pipeline market are AbbVie Inc, Aclaris Therapeutics Inc, Alexion Pharmaceuticals Inc, Aqilion AB, Ashvattha Therapeutics LLC, Astellas Pharma Inc, Bristol-Myers Squibb Co, and Celon Pharma SA. AbbVie Inc has the highest pipeline products.

Tyrosine Protein Kinase JAK1 Pipeline Market, by Companies

To know more about companies, download a free report sample

Market report overview

Key MoA	Tyrosine Protein Kinase JAK1 Inhibitor
Key RoA	Oral, Topical, Ophthalmic, Cutaneous, Inhalational, and Intravitreal
Key molecule type	Small Molecule
Key companies	AbbVie Inc, Aclaris Therapeutics Inc, Alexion Pharmaceuticals Inc, Aqilion AB, Ashvattha Therapeutics LLC, Astellas Pharma Inc, Bristol-Myers Squibb Co, and Celon Pharma SA

Scope

The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)
The report reviews Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
The report assesses Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics

Reasons to Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

AbbVie Inc
Aclaris Therapeutics Inc
Alexion Pharmaceuticals Inc
Aqilion AB
Ashvattha Therapeutics LLC
Astellas Pharma Inc
Bristol-Myers Squibb Co
Celon Pharma SA
Concert Pharmaceuticals Inc
Dizal (Jiangsu) Pharmaceutical Co Ltd
Eli Lilly and Co
EQRx Inc
Galapagos NV
GlaxoSmithKline Plc
Han Wha Pharma Co Ltd
Hangzhou East China Pharmaceutical Group Co Ltd
HK inno.N Corp
Impetis Biosciences Ltd
Incyte Corp
Japan Tobacco Inc
Jiangsu Carephar Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Vcare PharmaTech Co Ltd
Kinaset Therapeutics Inc
Lynk Pharmaceutical Hangzhou Co Ltd
Merck & Co Inc
Nippon Shinyaku Co Ltd
Pfizer Inc
Sareum Holdings Plc
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Sichuan Kelun Bio-Tech Pharmaceutical Co Ltd
Sierra Oncology Inc
Simcere Pharmaceutical Group Ltd
The United Laboratories International Holdings Ltd
Theravance Biopharma Inc
TLL Pharmaceutical LLC
Wuxi Fuxin Pharmaceutical Research and Development Co Ltd

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) – Overview

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) – Companies Involved in Therapeutics Development

AbbVie Inc

Aclaris Therapeutics Inc

Alexion Pharmaceuticals Inc

Aqilion AB

Ashvattha Therapeutics LLC

Astellas Pharma Inc

Bristol-Myers Squibb Co

Celon Pharma SA

Concert Pharmaceuticals Inc

Dizal (Jiangsu) Pharmaceutical Co Ltd

Eli Lilly and Co

EQRx Inc

Galapagos NV

GlaxoSmithKline Plc

Han Wha Pharma Co Ltd

Hangzhou East China Pharmaceutical Group Co Ltd

HK inno.N Corp

Impetis Biosciences Ltd

Incyte Corp

Japan Tobacco Inc

Jiangsu Carephar Pharmaceutical Co Ltd

Jiangsu Hengrui Medicine Co Ltd

Jiangsu Vcare PharmaTech Co Ltd

Kinaset Therapeutics Inc

Lynk Pharmaceutical Hangzhou Co Ltd

Merck & Co Inc

Nippon Shinyaku Co Ltd

Pfizer Inc

Sareum Holdings Plc

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Shenzhen Chipscreen Biosciences Co Ltd

Sichuan Kelun Bio-Tech Pharmaceutical Co Ltd

Sierra Oncology Inc

Simcere Pharmaceutical Group Ltd

The United Laboratories International Holdings Ltd

Theravance Biopharma Inc

TLL Pharmaceutical LLC

Wuxi Fuxin Pharmaceutical Research and Development Co Ltd

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) – Drug Profiles

(elsubrutinib + upadacitinib) – Drug Profile

Product Description

Mechanism Of Action

History of Events

A-223 – Drug Profile

Product Description

Mechanism Of Action

abrocitinib – Drug Profile

Product Description

Mechanism Of Action

History of Events

AQ-280 – Drug Profile

Product Description

Mechanism Of Action

History of Events

ARQ-255 – Drug Profile

Product Description

Mechanism Of Action

History of Events

ATI-1777 – Drug Profile

Product Description

Mechanism Of Action

History of Events

ATI-501 – Drug Profile

Product Description

Mechanism Of Action

History of Events

baricitinib – Drug Profile

Product Description

Mechanism Of Action

History of Events

CDD-2603 – Drug Profile

Product Description

Mechanism Of Action

History of Events

cerdulatinib – Drug Profile

Product Description

Mechanism Of Action

History of Events

CJ-15314 – Drug Profile

Product Description

Mechanism Of Action

History of Events

CPL-409116 – Drug Profile

Product Description

Mechanism Of Action

History of Events

CS-12192 – Drug Profile

Product Description

Mechanism Of Action

delgocitinib – Drug Profile

Product Description

Mechanism Of Action

History of Events

deuruxolitinib phosphate – Drug Profile

Product Description

Mechanism Of Action

History of Events

Drugs to Inhibit JAK1 for Autoimmune Disorders – Drug Profile

Product Description

Mechanism Of Action

DZD-4205 – Drug Profile

Product Description

Mechanism Of Action

History of Events

EQ-121 – Drug Profile

Product Description

Mechanism Of Action

History of Events

filgotinib maleate – Drug Profile

Product Description

Mechanism Of Action

History of Events

FZJ-003 – Drug Profile

Product Description

Mechanism Of Action

History of Events

GLPG-0555 – Drug Profile

Product Description

Mechanism Of Action

History of Events

GLPG-3121 – Drug Profile

Product Description

Mechanism Of Action

History of Events

INCB-54707 – Drug Profile

Product Description

Mechanism Of Action

History of Events

itacitinib adipate – Drug Profile

Product Description

Mechanism Of Action

History of Events

ivarmacitinib sulfate – Drug Profile

Product Description

Mechanism Of Action

History of Events

KFPH-018 – Drug Profile

Product Description

Mechanism Of Action

LNK-01001 – Drug Profile

Product Description

Mechanism Of Action

History of Events

momelotinib dihydrochloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

NS-229 – Drug Profile

Product Description

Mechanism Of Action

OB-756 – Drug Profile

Product Description

Mechanism Of Action

Opzelura – Drug Profile

Product Description

Mechanism Of Action

History of Events

peficitinib hydrobromide – Drug Profile

Product Description

Mechanism Of Action

History of Events

PNQ-401 – Drug Profile

Product Description

Mechanism Of Action

History of Events

PNQ-701 – Drug Profile

Product Description

Mechanism Of Action

History of Events

ruxolitinib phosphate – Drug Profile

Product Description

Mechanism Of Action

History of Events

SAR-20347 – Drug Profile

Product Description

Mechanism Of Action

History of Events

SDC-1801 – Drug Profile

Product Description

Mechanism Of Action

History of Events

SDC-1802 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit JAK1 and TYK2 for Rheumatoid Arthritis – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit JAK1 for Rheumatoid Arthritis – Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Inhibit JAK1, JAK2 and TYK2 for Diabetic Macular Edema – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit JAK1, JAK2, JAK3 and TYK2 for Asthma – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit JAK1, JAK2, JAK3 and TYK2 for Rheumatoid Arthritis – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit JAK1 and JAK3 for Inflammation – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit JAK1, JAK2, JAK3 and TYK2 for Dermatology – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Moleucle to Inhibit JAK 1 and JAK 2 for Inflammation – Drug Profile

Product Description

Mechanism Of Action

History of Events

TLL-018 – Drug Profile

Product Description

Mechanism Of Action

History of Events

upadacitinib ER – Drug Profile

Product Description

Mechanism Of Action

History of Events

VC-005 – Drug Profile

Product Description

Mechanism Of Action

History of Events

VR-588 – Drug Profile

Product Description

Mechanism Of Action

History of Events

WXFL-10203614 – Drug Profile

Product Description

Mechanism Of Action

WXSH-0150 – Drug Profile

Product Description

Mechanism Of Action

YJC-50018 – Drug Profile

Product Description

Mechanism Of Action

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) – Dormant Products

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) – Discontinued Products

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) – Product Development Milestones

Table

List of Tables

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products under Development by Indications, 2022 (Contd..1)

Number of Products under Development by Indications, 2022 (Contd..2)

Number of Products under Development by Indications, 2022 (Contd..3)

Number of Products under Development by Indications, 2022 (Contd..4)

Number of Products under Development by Indications, 2022 (Contd..5)

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Companies, 2022 (Contd..3)

Products under Development by Companies, 2022 (Contd..4)

Products under Development by Companies, 2022 (Contd..5)

Products under Development by Companies, 2022 (Contd..6)

Products under Development by Companies, 2022 (Contd..7)

Products under Development by Companies, 2022 (Contd..8)

Products under Development by Companies, 2022 (Contd..9)

Products under Development by Companies, 2022 (Contd..10)

Products under Development by Companies, 2022 (Contd..11)

Products under Development by Companies, 2022 (Contd..12)

Products under Development by Companies, 2022 (Contd..13)

Products under Development by Companies, 2022 (Contd..14)

Products under Development by Companies, 2022 (Contd..15)

Products under Development by Companies, 2022 (Contd..16)

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by AbbVie Inc, 2022

Pipeline by Aclaris Therapeutics Inc, 2022

Pipeline by Alexion Pharmaceuticals Inc, 2022

Pipeline by Aqilion AB, 2022

Pipeline by Ashvattha Therapeutics LLC, 2022

Pipeline by Astellas Pharma Inc, 2022

Pipeline by Bristol-Myers Squibb Co, 2022

Pipeline by Celon Pharma SA, 2022

Pipeline by Concert Pharmaceuticals Inc, 2022

Pipeline by Dizal (Jiangsu) Pharmaceutical Co Ltd, 2022

Pipeline by Eli Lilly and Co, 2022

Pipeline by EQRx Inc, 2022

Pipeline by Galapagos NV, 2022

Pipeline by GlaxoSmithKline Plc, 2022

Pipeline by Han Wha Pharma Co Ltd, 2022

Pipeline by Hangzhou East China Pharmaceutical Group Co Ltd, 2022

Pipeline by HK inno.N Corp, 2022

Pipeline by Impetis Biosciences Ltd, 2022

Pipeline by Incyte Corp, 2022

Pipeline by Japan Tobacco Inc, 2022

Pipeline by Jiangsu Carephar Pharmaceutical Co Ltd, 2022

Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022

Pipeline by Jiangsu Vcare PharmaTech Co Ltd, 2022

Pipeline by Kinaset Therapeutics Inc, 2022

Pipeline by Lynk Pharmaceutical Hangzhou Co Ltd, 2022

Pipeline by Merck & Co Inc, 2022

Pipeline by Nippon Shinyaku Co Ltd, 2022

Pipeline by Pfizer Inc, 2022

Pipeline by Sareum Holdings Plc, 2022

Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, 2022

Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2022

Pipeline by Sichuan Kelun Bio-Tech Pharmaceutical Co Ltd, 2022

Pipeline by Sierra Oncology Inc, 2022

Pipeline by Simcere Pharmaceutical Group Ltd, 2022

Pipeline by The United Laboratories International Holdings Ltd, 2022

Pipeline by Theravance Biopharma Inc, 2022

Pipeline by TLL Pharmaceutical LLC, 2022

Pipeline by Wuxi Fuxin Pharmaceutical Research and Development Co Ltd, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

Dormant Products, 2022 (Contd..2)

Dormant Products, 2022 (Contd..3)

Dormant Products, 2022 (Contd..4)

Discontinued Products, 2022

Discontinued Products, 2022 (Contd..1)

Discontinued Products, 2022 (Contd..2)

Figures

List of Figures

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Type, 2022

Frequently asked questions

What are the key MoA in the Tyrosine Protein Kinase JAK1 pipeline market?

The key MoA in the Tyrosine Protein Kinase JAK1 pipeline market is Tyrosine Protein Kinase JAK1 Inhibitor.
What are the key RoA in the Tyrosine Protein Kinase JAK1 pipeline market?

The key RoA in the Tyrosine Protein Kinase JAK1 pipeline market are oral, topical, ophthalmic, cutaneous, inhalational, and intravitreal.
What are the key molecule types in the Tyrosine Protein Kinase JAK1 pipeline market?

The key molecule types in the Tyrosine Protein Kinase JAK1 pipeline market is small molecule.
What are the key companies in the Tyrosine Protein Kinase JAK1 pipeline market?

The key companies in the Tyrosine Protein Kinase JAK1 pipeline market are AbbVie Inc, Aclaris Therapeutics Inc, Alexion Pharmaceuticals Inc, Aqilion AB, Ashvattha Therapeutics LLC, Astellas Pharma Inc, Bristol-Myers Squibb Co, and Celon Pharma SA.

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports

Currency USD

Single User

$3,500

Can be used by individual purchaser only

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more Other Diseases reports

Pharmaceuticals

New

Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…

Pharmaceuticals

New

Cell and Gene Therapies in Ophthalmology - Disease Overview, Treatment…

Pharmaceuticals

New

Clinical Trials Scorecard for Investigations in 2023

Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

Access a live Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
Fuel your decision making with real-time deal coverage and media activity.
Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.

Tell me more

Reports

Reports by Sector

Report Type

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Key MoA in the Tyrosine Protein Kinase JAK1 Pipeline Market

Key RoA in the Tyrosine Protein Kinase JAK1 Pipeline Market

Key Molecule Types in the Tyrosine Protein Kinase JAK1 Pipeline Market

Key Companies in the Tyrosine Protein Kinase JAK1 Pipeline Market

Market report overview

Reasons to Buy

Table of Contents

Table

Figures

Frequently asked questions

Undecided about purchasing this report?

Get in touch to find out about multi-purchase discounts

Related reports